As ROI across R&D investments in big phama declines, companies look for new and innovative ways to access and nurture innovation via partnerships and through the use of new data types. In the process, the business models, products, and role of big pharma in healthcare is changing.
Author: Melanie Senior
Published: 20 June 2018
Number of pages:6
Big pharma is feeling the pressure as return on investment for R&D is no longer guaranteed to result in big dividends. Explore the changes that are occurring for pharma giants as they seek new partnerships, new data, and more. Read about their efforts to transform their business models and products and forge a new role in healthcare as they compete with increasing competition from innovative smaller companies. Hear about the new tactics being adopted by Novartis, J&J, and Bayer, and examine the potential impact of these changes on your business.
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.